Panmure Gordon restated their buy rating on shares of Allergy Therapeutics plc (LON:AGY) in a report issued on Thursday.

A number of other equities research analysts also recently issued reports on the stock. Numis Securities Ltd reaffirmed a buy rating and set a GBX 45 ($0.61) price target on shares of Allergy Therapeutics plc in a research note on Friday, September 22nd. FinnCap reiterated a buy rating and set a GBX 46 ($0.62) price objective on shares of Allergy Therapeutics plc in a research report on Thursday, August 24th.

Shares of Allergy Therapeutics plc (AGY) opened at 33.00 on Thursday. The firm’s market cap is GBX 196.06 million. Allergy Therapeutics plc has a 52 week low of GBX 19.00 and a 52 week high of GBX 34.00. The firm has a 50-day moving average of GBX 29.82 and a 200 day moving average of GBX 27.76.

COPYRIGHT VIOLATION WARNING: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/02/allergy-therapeutics-plcs-agy-buy-rating-reiterated-at-panmure-gordon.html.

Allergy Therapeutics plc Company Profile

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Stock Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related stocks with our FREE daily email newsletter.